Curis, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRIS research report →
Price Chart
About the company
Curis, Inc. , a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
- CEO
- James Dentzer
- IPO
- 2000
- Employees
- 22
- HQ
- Lexington, MA, US
Get TickerSpark's AI analysis on CRIS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $832.65K
- P/E
- -0.07
- Fwd P/E
- 0.30
- PEG
- -0.00
- P/S
- 0.80
- P/B
- 0.77
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
- Gross Margin
- 97.72%
- Op Margin
- -3319.60%
- Net Margin
- -1893.15%
- ROE
- -339.08%
- ROIC
- -1147.89%
Latest fiscal year · YoY change
- Revenue
- $9.44M-13.4%
- Gross Profit
- $9.40M-13.1%
- Op Income
- $-32,902,000
- Net Income
- $-7,582,000+82.5%
- EPS
- $-11.60+91.6%
- OCF Growth
- +31.2%
- FCF Growth
- +31.2%
- 52W High
- $28.40
- 52W Low
- $0.33
- 50D MA
- $0.69
- 200D MA
- $7.71
- Beta
- 3.25
- RSI (14)
- 40
- Avg Volume
- 4.33M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Curis said its PCNSL program continues to show encouraging response rates, while CLL initial data are expected by year-end and cash is expected to support operations into 2027.· November 12, 2026
- PCNSL TakeAim data remained the lead story, with 86% response in BTKi-naive patients (6 of 7) and 26% response in salvage-line patients (10 of 39).
- Management said those results continue to support the potential for accelerated approval submissions in the U.S. and Europe.
- The company expects full enrollment in the PCNSL registrational study by the end of 2027, with an NDA filing potentially in 2028 after follow-up.
- In CLL, Curis has 11 sites open and 12 patients on study, with initial data planned for later this year.
- Cash and cash equivalents were $5 million at September 30, 2026, and management said existing cash plus October financing should fund operations into 2027.
Curis reported third-quarter 2026 net loss of $8.1 million, or $1.94 per share, versus a net loss of $7.7 million, or $9.86 per share, in the third quarter of 2025. For the first nine months of 2026, net loss was $40.9 million, or $16.77 per share, versus $26.9 million, or $43.82 per share, in the same period of 2025. Third-quarter 2026 R&D expense was $5.6 million versus $6.4 million a year ago, and G&A was $3.2 million versus $3.7 million. Cash and cash equivalents were $5 million at September 30, 2026, and management said current cash plus October financing should fund operations into 2027. In PCNSL, updated data showed an 86% response rate in 7 BTKi-naive patients and a 26% response rate in 39 salvage-line patients. Management expects full enrollment in the PCNSL study by the end of 2027, with an NDA filing for accelerated approval in 2028 if the current pace holds.
Jim Dentzer struck an optimistic tone around emavusertib’s potential across NHL subtypes, emphasizing that the PCNSL response rates remain meaningful in a rare and hard-to-treat disease. He said the combination appears better than BTKi alone in BTKi-naive PCNSL and that the salvage-line activity is encouraging because those patients have very poor prognoses. On CLL, he framed the study as an attempt to improve on BTKi monotherapy by enabling deeper responses, including potential complete remission or undetectable MRD and possibly time-limited treatment.
Diantha Duvall focused on the quarter’s financial results and cash position. She reported Q3 2026 net loss of $8.1 million, R&D expense of $5.6 million, and G&A of $3.2 million; for the nine-month period, net loss was $40.9 million, R&D was $18.8 million, and G&A was $11.4 million. She also said Curis had $5 million in cash and cash equivalents at September 30, 2026, and that existing cash plus financing completed in October should be sufficient to fund operations into 2027.
Analysts focused mainly on the CLL readout and the PCNSL timeline. Management said the CLL dataset will be limited to the patients treated so far, with varying maturity, and that the company will disclose as much safety and activity data as it has by year-end, but exact content and venue were still to be determined. On PCNSL, management said enrollment has been choppy because the disease is ultra-orphan, but it is consistent and close to completion; they reiterated full enrollment by end-2027 and suggested an NDA filing could follow in 2028 after about 6 months of follow-up from last patient in.
The call reinforced that Curis is seeing clinically meaningful activity in its lead PCNSL program, including a high response rate in BTKi-naive patients and activity even in salvage-line disease. Management also sounded confident that the same dual-blockade approach could show benefit in CLL, with data expected soon and the potential for a broader treatment paradigm shift if activity is confirmed.
Enrollment in PCNSL remains slow because the disease is ultra-rare, pushing full enrollment out to the end of 2027 and an NDA potentially to 2028. Financially, the company remains highly dependent on financing, with just $5 million in cash at quarter-end and a plan that relies on the October financing to fund operations into 2027. The CLL program is still early, with only 12 patients enrolled and no efficacy data yet disclosed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 82.8%
- Shares Outstanding
- 1.95M
- Float Shares
- 1.61M
of shares held by institutions
37 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Armistice Capital, LLC | 372.00K | ▲ 372.00K |
| Vanguard Group Inc | 366.11K | ▼ 1.51K |
| Bleichroeder LP | 190.12K | ▼ 3.61M |
| Dauntless Investment Group, LLC | 100.00K | ▲ 90.00K |
| Nantahala Capital Management, LLC | 93.82K | ▼ 1.89M |
| Morgan Stanley | 87.34K | ▼ 416.96K |
| Cable Car Capital, LP | 66.67K | ▼ 1.27M |
| Maverick Capital Ltd | 49.55K | 0 |
| Two Sigma Investments, LP | 43.93K | ▲ 43.93K |
| Hrt Financial LP | 41.45K | ▲ 41.45K |
| Sphera Funds Management Ltd. | 39.66K | ▼ 59.33K |
| Vanguard Capital Management LLC | 29.19K | ▼ 314.65K |
Held by 6 ETFs
Biggest fund positions in CRIS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 7, 26 | Rubin Marc | other | 6,800 |
| Jul 7, 26 | KAITIN KENNETH I | other | 6,800 |
| Jul 7, 26 | Hohneker John | other | 6,800 |
| Jul 7, 26 | GREENACRE MARTYN D | other | 6,800 |
| Jul 7, 26 | Borgman Anne Elizabeth | other | 6,800 |
| Jul 7, 26 | Duvall Diantha | other | 48,285 |
| Jul 7, 26 | Zung Jonathan B. | other | 48,285 |
| Jul 7, 26 | Dentzer James E | other | 110,090 |
| Mar 31, 26 | KAITIN KENNETH I | buy | 10,000 |
| Mar 20, 26 | Zung Jonathan B. | other | 66,667 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CRIS coverage
Recent articles, reports, and earnings notes.
No research on CRIS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CRIS report →Curis, Inc. (CRIS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Curis Provides Third Quarter 2026 Business Update
prnewswire.com · Nov 12
Curis to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on November 12, 2026
prnewswire.com · Nov 5
Curis, Inc. Announces Pricing of $8.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules with Existing Healthcare Focused Institutional Investors
prnewswire.com · Oct 16
Curis, Inc. Announces Pricing of $5.6 Million Public Offering
prnewswire.com · Aug 13
Curis Doses First Five Patients in TakeAim CLL Study
prnewswire.com · Jul 30
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
benzinga.com · Jul 24
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript
seekingalpha.com · Jul 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.